Phase I study of detoxified Escherichia coli J5 lipopolysaccharide (J5dLPS)/group B meningococcal outer membrane protein (OMP) complex vaccine in human subjects.

[1]  G. Clermont,et al.  Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care , 2001, Critical care medicine.

[2]  S. Opal,et al.  Active immunization with a detoxified Escherichia coli J5 lipopolysaccharide group B meningococcal outer membrane protein complex vaccine protects animals from experimental sepsis. , 2001, The Journal of infectious diseases.

[3]  S. Romero-Steiner,et al.  Comparison of an opsonophagocytic assay and IgG ELISA to assess responses to pneumococcal polysaccharide and pneumococcal conjugate vaccines in children and young adults with sickle cell disease. , 2000, The Journal of infectious diseases.

[4]  J. Seoh,et al.  Evaluation of antibody responses to pneumococcal vaccines with ELISA and opsonophagocytic assay. , 1999, Journal of Korean medical science.

[5]  M. S. Rangel-Frausto,et al.  The epidemiology of bacterial sepsis. , 1999, Infectious disease clinics of North America.

[6]  C. Natanson,et al.  Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. , 1997, Critical care medicine.

[7]  Wayne N. Campbell,et al.  Immunogenicity of a 24-valent Klebsiella capsular polysaccharide vaccine and an eight-valent Pseudomonas O-polysaccharide conjugate vaccine administered to victims of acute trauma. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  S. Opal,et al.  A noncovalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc chemotype) lipopolysaccharide and Neisseria meningitidis Group B outer membrane protein produces protective antibodies against gram-negative bacteremia. , 1996, The Journal of infectious diseases.

[9]  J. Ryan,et al.  Novel Therapeutic Strategies in the Treatment of Sepsis , 1995 .

[10]  S. Opal,et al.  Affinity-purified Escherichia coli J5 lipopolysaccharide-specific IgG protects neutropenic rats against gram-negative bacterial sepsis. , 1994, The Journal of infectious diseases.

[11]  Jerome J. Schentag,et al.  A Controlled Clinical Trial of E5 Murine Monoclonal IgM Antibody to Endotoxin in the Treatment of Gram-Negative Sepsis , 1991 .

[12]  M. A. Martin,et al.  A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. , 1991, JAMA.

[13]  S. Capewell,et al.  INTRAMUSCULAR TRIAMCINOLONE IN SEVERE ASTHMA. REPLIES , 1991 .

[14]  C. Sprung,et al.  Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. , 1991 .

[15]  C. Raetz,et al.  Lipid IVA inhibits synthesis and release of tumor necrosis factor induced by lipopolysaccharide in human whole blood ex vivo , 1990, The Journal of experimental medicine.

[16]  D. Gocke,et al.  Characterization of the human antibody response to an Escherichia coli O111:B4 (J5) vaccine. , 1988, The Journal of infectious diseases.

[17]  W. R. Mccabe,et al.  Immunization with rough mutants of Salmonella minnesota: initial studies in human subjects. , 1988, The Journal of infectious diseases.

[18]  J. Schellekens,et al.  Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind, randomized trial. , 1988, The Journal of infectious diseases.

[19]  R. Wenzel,et al.  The mortality of hospital-acquired bloodstream infections: need for a new vital statistic? , 1988, International journal of epidemiology.

[20]  J. McCutchan,et al.  TREATMENT OF GRAM-NEGATIVE BACTEREMIA AND SHOCK WITH HUMAN ANTISERUM TO A MUTANT ESCHERICHIA COLI , 1983 .

[21]  D. Tyrrell.  New Developments with Human and Veterinary Vaccines , 1981 .

[22]  J. Griffiss,et al.  Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man. , 1979, The Journal of clinical investigation.

[23]  C. Galanos,et al.  A new method for the extraction of R lipopolysaccharides. , 1969, European journal of biochemistry.

[24]  J. Helterbrand,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis , 2003 .

[25]  S. Opal,et al.  New Trends in Escherichia coli O111:B4 J5 Mutant (Rc chemotype) Vaccine Development for Use in Gram-Negative Bacillary Sepsis, , 1995 .

[26]  W. R. Mccabe,et al.  Potential use of shared antigens for immunization against gram-negative bacillary infections. , 1980, Progress in clinical and biological research.

[27]  F. Smith,et al.  COLORIMETRIC METHOD FOR DETER-MINATION OF SUGAR AND RELATED SUBSTANCE , 1956 .